PTAB Denies Institution of One Elevidys® IPR and Institutes Another

Why It Matters

The mixed PTAB outcomes could reshape the enforceability of Elevidys patents and affect Sarepta’s revenue outlook, while setting precedent for biotech patent challenges involving analytical ultracentrifugation methods.

Key Takeaways

• Sarepta's Elevidys generated $898.7 million net revenue in 2025
• PTAB denied institution of IPR 2026‑00149 on Patent 12,013,326
• PTAB granted institution of IPR 2026‑00150 on Patent 12,031,894
• Outcomes affect ongoing litigation (Case 24‑cv‑00882) between Sarepta and Genzyme

Pulse Analysis

The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) plays a pivotal role in adjudicating inter partes reviews, a mechanism that allows competitors to challenge the validity of granted patents. In May 2026, the Board issued bulk‑order decisions on two IPRs filed by Sarepta Therapeutics against Genzyme’s patents tied to Elevidys, a gene‑therapy product for Duchenne muscular dystrophy. While the denial of IPR 2026‑00149 signals that the challenged claims on analytical ultracentrifugation methods lack a clear path to invalidation, the grant of IPR 2026‑00150 demonstrates that at least one claim may be vulnerable, underscoring the nuanced nature of patent validity assessments in the biotech sector.

The divergent outcomes have immediate strategic implications. A denied institution preserves the enforceability of Patent 12,013,326, allowing Genzyme to continue leveraging that claim in licensing negotiations and litigation. Conversely, the granted institution of Patent 12,031,894 opens the door for potential claim invalidation, which could erode Sarepta’s defensive moat around Elevidys and affect royalty streams. Both decisions intersect with the ongoing federal case (24‑cv‑00882), meaning that courtroom arguments may now incorporate PTAB findings, potentially accelerating settlement discussions or prompting additional patent filings to shore up the portfolio.

From a market perspective, the PTAB rulings arrive as Sarepta reports nearly $900 million in Elevidys revenue, highlighting the product’s commercial significance. Investors watch such patent disputes closely, as they can materially impact future earnings and valuation of biotech firms. The case also illustrates a broader trend: as gene‑therapy technologies mature, the USPTO and PTAB are increasingly tasked with evaluating sophisticated scientific methods, shaping the competitive landscape for next‑generation therapeutics.